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Abstract
Background: The aqueous extract of a Brazilian palm-tree fruit - the babassu - (BAE) exerts a clear
immunostimulative activity in vivo. In the present work, the possibility that BAE can promote Th1 immune
responses in mice of a Th2 immune response-prone strain - the BALB/c was investigated. BAE itself, and
preparations consisting of Leishmania amazonensis promastigote extract (LE), adsorbed or not to Al(OH)3, and in
the presence or not of BAE, were used as immunogens. LE and Al(OH)3 have been shown to preferentially elicit
Th2 immune responses.
Results: The addition of BAE to LE-containing immunogenic preparations, adsorbed or not to Al(OH)3, clearly
promoted the in vitro production of interferon g (IFN-g), a major Th1-dependent cytokine, and not of interleukin
(IL-)4 (a Th2-dependent cytokine), by LE-stimulated splenocytes of immunized BALB/c mice. It also promoted the
in vivo formation of IgG2a anti-LE antibodies. However, immunization with LE by itself led to an increased
production of IL-4 by LE-stimulated splenocytes, and this production, albeit not enhanced, was not reduced by the
addition of BAE to the immunogen. On the other hand, the IL-4 production by LE-stimulated splenocytes was
significantly lower in mice immunized with a preparation containing Al(OH)3-adsorbed LE and BAE than in mice
immunized with the control preparation of Al(OH)3-adsorbed LE without BAE. Moreover, an increased production
of IFN-g, and not of IL-4, was observed in the culture supernatants of splenocytes, from BAE-immunized mice,
which were in vitro stimulated with BAE or which received no specific in vitro stimulus. No differences in IL-10 (an
immunoregulatory cytokine) levels in the supernatants of splenocytes from mice that were injected with BAE, in
relation to splenocytes from control mice, were observed. The spontaneous ex vivo production of NO by
splenocytes of mice that had been injected with BAE was significantly higher than the production of NO by
splenocytes of control mice.
Conclusions: Based on the results described above, BAE, or biologically active molecules purified from it, should be
further investigated as a possible adjuvant, in association or not with aluminium compounds, for the preferential
induction of Th1-dependent immune responses against different antigens in distinct murine strains and animal species.
Background
Th1-dependent immune responses have been shown to
protect mammals against many clinically relevant intra-
cellular pathogens, such as Mycobaterium tuberculosis,
Leishmania sp., and human herpes virus, and even
against some extracellular pathogens, such as Candida
albicans [1-4]. Adjuvants for Th1 immune responses
could be, therefore, crucial components of a vaccine
against this type of pathogens [5,6].
Different compounds have been tested for safety and
adjuvant activity in human beings. Aluminum hydroxide,
aluminum phosphate and Montanide
®, a new generation
o fw a t e ri no i le m u l s i o n s ,a r es t i l lt h eo n l ya d j u v a n t s
licensed for use in humans [7-9]. Lack of detailed data on
safety, dose and routes of immunization has restricted to
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shown to be more potent or more directed to Th1
immune responses than the aluminum compounds
[10-12].
The babassu (Orbignya phalerata, Mart, Arecaceae) is a
palm tree commonly found in the northeast of Brazil.
Babassu fruit flower is frequently used as food or folk
medicine. Several important biological properties have
been assigned to the babassu mesocarp flour, including an
immunomodulatory activity [13]. It can increase the pro-
duction of anti-insulin IgM antibodies in mice [14,15] and
anti-thyroglobulin antibodies in rats [16]. In addition, the
oral administration of an aqueous extract of babassu
mesocarp to mice increased the production of inflamma-
tory mediators (such as hydrogen peroxide, nitric oxide
and TNF-a) by peritoneal macrophages ex vivo and the
influx of leukocytes to the peritoneal cavity [17]. These
known immunostimulative effects of the babassu aqueous
extract (BAE) have motivated the present investigation on
its possible immunoadjuvant activity. Immunization proto-
cols utilizing immunogenic preparations that were likely to
induce polarized Th2-dependent immune responses,
namely Leishmania promastigote extract (LE) and Al(OH)
3 gel-adsorbed LE [18-20], were used. As described below,
the injection of BAE preferentially stimulated the Th1
component of the anti-LE and the anti-BAE immune
responses in the immunized mice.
Results
Anti-LE antibody levels
The addition of BAE to the antigenic preparations (both
to LE or Al(OH)3 gel-adsorbed LE) led to significantly
increased levels of serum anti-LE IgG2a antibodies in
the immunized mice (Figure 1A, groups “LE + BAE”
and “LE-Al(OH)3 + BAE”) in relation to the correspond-
ing control mice that did not receive BAE (Figure 1A,
groups “LE” and “LE-Al(OH)3“). The co-administration
of BAE also led to a statistically significant increase in
anti-LE IgG1 antibodies in the LE-immunized mice that
have not received Al(OH)3 (Figure 1B, group “LE +
BAE”) in relation to the mice that were immunized only
with LE, without adjuvants (Figure 1B, group “LE”).
However, the addition of BAE to the Al(OH)3-adsorbed
LE preparation led to a statistically significant decrease
in IgG1 anti-LE antibody levels in the immunized mice
(Figure 1B, group “LE-Al(OH)3 +B A E ”), in relation to
t h em i c et h a tw e r ei m m u n i z e dw i t hA l ( O H ) 3-adsorbed
LE without BAE (Figure 1B, group “LE-Al(OH)3“). The
results obtained with the use of BAE as adjuvant did not
differ significantly from the results obtained with the use
of CFA as adjuvant, both for IgG2a or IgG1 antibody
levels (Figure 1). However, mice immunized with LE
associated with both BAE and Al(OH)3 (Figure 1B,
group “LE-Al(OH)3 +B A E ”) had significantly lower
levels of anti-LE IgG1 antibodies than mice immunized
with CFA-emulsified LE (Figure 1B, group “LE + CFA”).
Cytokine responses in non-stimulated and in LE- and
BAE-stimulated cultures
When stimulated in vitro with LE, the splenocytes from
the mice that were immunized with LE and received
BAE as adjuvant (Figure 2A group “LE + BAE”)p r o -
duced significantly higher concentrations of interferon g
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Figure 1 IgG1 and IgG2a anti-Leishmania promastigote extract
(LE) antibody levels in mice immunized with LE, associated or
not with babassu aqueous extract (BAE). IgG2a (A) and IgG1
(B) antibodies were detected by ELISA as detailed in the Material
and Methods, in sera prepared from blood samples collected
10 days after the end of the immunization. Groups of five to eight
BALB/c mice were immunized by two subcutaneous injections of
LE, associated with BAE (LE + BAE), or of Al(OH)3-adsorbed LE, also
associated with BAE (LE-Al(OH)3 + BAE), 14 days apart. Groups of
control mice were also immunized with LE emulsified in complete
Freund’s adjuvant (LE + CFA), with LE without BAE (LE), and with Al
(OH)3-adsorbed LE without BAE (LE-Al(OH)3), following the same
immunization protocol. Each injection contained a total of 250 μg
of LE and/or 5 mg of BAE. A negative control group was injected
with a saline solution in place of the immunizing injections (Saline).
The boxes represent the 10-90 percentile intervals and the median
values of the results, and the vertical bars the value ranges. P <
0.001, Kruskal-Wallis test. *, P ≤ 0.007; **, P ≤ 0.003; ***, P ≤ 0.009;
****, P ≤ 0.016; Mann-Whitney U test.
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Page 2 of 8(IFN-g) than the splenocytes from the mice that were
immunized with LE without BAE (Figure 2A, group
“LE”). The same result was observed when the mice
were immunized with Al(OH)3-adsorbed LE and
received BAE as adjuvant (Figure 2A, group “LE-Al(OH)
3 +B A E ”). When stimulated in vitro with LE, the sple-
nocytes from these mice produced significantly higher
concentrations of IFN-g than the splenocytes from mice
that were immunized with Al(OH)3 gel-adsorbed LE
without BAE (Figure 2A, group “LE-Al(OH)3“). The
amounts of IFN-g produced by splenocytes of the mice
that received BAE, i.e., the mice that were immunized
either with LE in the presence of BAE (Figure 2A, group
“LE + BAE”) or with Al(OH)3-adsorbed LE also in the
presence of BAE (Figure 2A, group “LE-Al(OH)3 +
BAE”), were comparable to those produced by spleno-
cytes from the mice that were immunized with CFA-
emulsified LE (Figure 2A, group “LE + CFA"; P >0 . 0 5 ,
Mann-Whitney U test).
The production of interleukin (IL-)4 by LE-stimulated
splenocytes was either not altered by the addition of
BAE to the immunogenic preparations (in the case of
mice immunized with LE; Figure 2B, group “LE + BAE”,
P > 0.05, Mann-Whitney U test), or was significantly
reduced (in the case of mice immunized with Al(OH)3
gel-adsorbed LE; Figure 2B, group “LE-Al(OH)3 + BAE”,
P < 0.001, Mann-Whitney U test), in relation to the
corresponding control mice that did not receive BAE
(Figure 2B, groups “LE” and “LE-Al(OH)3“, respectively).
The production of IFN-g, and not of IL-4, was signifi-
cantly higher in BAE-stimulated cultures of splenocytes
from BAE-immunized mice, than in splenocyte cultures
from saline-treated control mice (Figure 3A and 3B).
Spleen cells from the mice that had been immunized
with BAE spontaneously produced, ex vivo,m o r eI F N - g
than control saline-treated mice (Figure 3C). No statisti-
cally significant difference in the spontaneous produc-
tion of IL-4 by splenocytes of BAE-immunized and
saline-treated mice was observed (Figure 3D).
No statistically significant differences in IL-10 produc-
tion by unstimulated, LE-stimulated, or BAE-stimulated
splenocytes from the immunized and the non-immu-
nized mice were observed (data not shown).
Nitric oxide production
The concentrations of nitric oxide in splenic cell superna-
tants from mice of the groups immunized with BAE or
with BAE-containing preparations (Figure 4; groups
“BAE”, “LE + BAE”, and LE-Al(OH)3 + BAE) were signifi-
cantly higher than in those from mice of the correspond-
ing control groups, which were treated with saline only or
immunized with preparations without BAE (Figure 4;
groups “Saline”, “LE”, and LE-Al(OH)3, respectively). The
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Figure 2 Concentrations of IFNg and IL-4 in the supernatants
of splenocyte cultures from BALB/c mice immunized with
Leishmania promastigote extract (LE), associated or not with
babassu aqueous extract (BAE). Splenocytes (from spleens
collected ten days after the end of the immunization) were
stimulated with LE and concentrations of IFNg (A) and IL-4 (B)i n
the supernatants were measured by ELISA. Groups of five to 12
animals were immunized by two subcutaneous injections of LE,
associated with BAE (LE + BAE) or of Al(OH)3 gel-adsorbed LE, also
associated with BAE (LE-Al(OH)3 + BAE), 14 days apart. Groups of
control mice were also immunized with LE emulsified in complete
Freund’s adjuvant (LE + CFA), with LE without BAE (LE), and with Al
(OH)3-adsorbed LE without BAE (LE-Al(OH)3), following the same
immunization protocol. Each injection contained a total of 250 μg
of LE and/or 5 mg of BAE. A negative control group was injected
with a saline solution in place of the immunizing injections (Saline).
The boxes represent the 10-90 percentile intervals and the median
values of the results, and the vertical bars the value ranges. P <
0.001, Kruskal-Wallis test. *, P ≤ 0.004; **, P ≤ 0.003; ***, P ≤ 0.002;
****, P ≤ 0.001; ns, non significant; Mann-Whitney U test.
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Page 3 of 8concentrations of nitric oxide in splenic cell supernatants
from the positive control mice, which were immunized
with CFA-emulsified LE (Figure 4; group “LE + CFA”),
were also higher than the nitric oxide concentrations in
splenic cell supernatants from mice of their corresponding
control group (Figure 4; group “LE”).
Discussion
The purpose of this study was to investigate the efficacy,
as immunological adjuvant, of an aqueous extract of the
babassu mesocarp. This adjuvant activity was investi-
gated with the BAE in two different formulations: in
soluble form or adsorbed to Al(OH)3. In both cases, its
injection in mice stimulated a Th1-dependent immune
response, both to itself or to LE, as demonstrated by:
(i) a marked increase in circulating anti-LE IgG2a anti-
bodies; (ii) an increased in vitro production of IFN-g by
LE-or BAE-stimulated splenocytes; (iii) an increased ex
vivo production of IFN-g by unstimulated splenocytes,
and (iv) an increased ex vivo production of nitric oxide
by splenic cells. As expected, the immunization of
BALB/c mice with LE alone led to the significant pro-
duction of IL-4 by LE-stimulated splenocytes [18]. The
addition of BAE to the LE did not significantly augment
t h i sI L - 4p r o d u c t i o n .T h i sf i n d i n g ,t h e r e f o r e ,d o e sn o t
support the possibility that, in addition to promoting
Th1 immune responses, the BAE also enhances Th2
immune responses. On the other hand, a reduction in
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Figure 3 Concentrations of IFNg and IL-4 in the supernatants
of splenocyte cultures from babassu aqueous extract (BAE)-
immunized BALB/c mice. Splenocytes (prepared from spleens
collected ten days after the end of the immunization) were
stimulated with BAE (A and B), or unstimulated (C and D), and the
concentrations of IFNg (A and C) and IL-4 (B and D) in the
supernatants were measured by ELISA. Groups of five or six animals
were immunized by two subcutaneous injections of 250 μg of BAE,
14 days apart (BAE). Negative control groups of five or six animals
were injected with a saline solution in place of the immunizing
injections (Saline). The boxes represent the 10-90 percentile
intervals and the median values of the results, and the vertical bars
the value ranges. P < 0.001, Kruskal-Wallis test. *, P ≤ 0.004; ns, non
significant; Mann-Whitney U test.
Saline
BAE
LE
LE+BAE
3
LE-Al(OH)
 + BAE
3
LE-Al(OH)
LE + CFA
0
10
20
30
40
**
*
***
*
N
O
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
μ
M
)
Figure 4 Nitric oxide concentration in splenocyte cultures from
mice immunized with Leishmania promastigote extract (LE)
and babassu aqueous extract (BAE). Supernatants were obtained
from unstimulated spleen cells, i.e, spleen cells that were not
incubated with antigen in vitro. Spleens were collected ten days
after the end of the immunization from groups of five to nine
BALB/c mice that had been immunized with two subcutaneous
injections of LE associated with BAE (LE + BAE) or of Al(OH)3-
adsorbed LE associated with BAE (LE-Al(OH)3 + BAE), 14 days
apart. Groups of control mice were also immunized with LE
emulsified in complete Freund’s adjuvant (LE + CFA), with LE
without BAE (LE), and with Al(OH)3-adsorbed LE without BAE (LE-Al
(OH)3), following the same immunization protocol. Each injection
contained a total of 250 μg of LE and/or 5 mg of BAE. A negative
control group was injected with a saline solution in place of the
immunizing injections (Saline). The boxes represent the 10-90
percentile intervals and the median values of the results, and the
vertical bars the value ranges. P < 0.001, Kruskal-Wallis test. *, P ≤
0.003; **, P ≤ 0.005; ***, P ≤ 0.016; Mann-Whitney U test.
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Page 4 of 8IL-4 production by the antigen-stimulated splenocytes,
which could be expected from a Th1-polarising adju-
vant, was not seen in these mice. However, additional
results indicate that the BAE does preferentially enhance
Th1 immune responses, and even reduces a Th2-
dependent immune response. First, the addition of BAE to
the immunogenic preparation significantly reduced the
production of IL-4 by splenocytes from mice immunized
with Al(OH)3-adsorbed LE. The reason why it would exert
this inhibitory effect on the IL-4 production only when the
anti-LE immune response is concomitantly stimulated by
Al(OH)3 is not clear. It would not be surprising, however,
that the LE and the Al(OH)3 would promote Th2 immune
responses through different mechanisms, and it is possible
that the Al(OH)3-induced mechanism could be more
easily inhibited by immune manipulation than the LE-
induced mechanism. Second, in mice injected with BAE
alone, a recall immune response to antigens that were pre-
sent in the BAE was observed. This response was charac-
terized by significantly increased production of IFN-g, and
no significant differences in IL-4 production, by the
mouse splenocytes when they were subjected to stimula-
tion with BAE in vitro, in relation to the splenocytes of sal-
ine-injected control mice. An IFN-g response was already
significantly taking place in vivo, since splenocytes from
the BAE-immunized mice spontaneously produced signifi-
cant amounts of IFN-g, and not of IL-4, ex vivo,i nr e l a t i o n
to splenocytes from control, saline-treated mice.
No differences in IL-10 levels in the supernatants of
splenocytes from mice that were injected with BAE, in
relation to splenocytes from control mice, were
observed. This finding, which indicates that BAE is not
inducing leukocytes to produce IL-10, could perhaps
contribute to the stimulative effect of BAE on IFN-g-
producing immune responses, since IL-10 would tend to
down regulate those immune responses [21].
The addition of BAE to the LE preparation also led to
an increased production of IgG1 antibodies, apparently
conflicting with the absence of increased IL-4 produc-
tion by in vitro-stimulated splenocytes. However, IgG1
antibodies in mice have been shown to constitute two
different molecular sub-populations, one which can sen-
sitize mast cells and is dependent on IL-4 for its pro-
duction, and another that does not bind to mast cells
and depends on the Th1-inducing IL-12 cytokine to be
produced [22,23]. Thus, wher e a st h ep r e s e n c eo fI g G 2 a
antibodies can be considered a marker of an IFN-g -
producing Th1 immune response in most mouse strains,
including the BALB/c [24,25], the implication of the
presence of IgG1 antibodies, in terms of the nature of
the underlying immune response, is much less clear.
In this study, the Th1 immune response-promoting
activity of BAE was shown in mice of the BALB/c strain,
which are Th2-biased [26]. It could be expected,
therefore, that the Th1-promoting effect would be even
more pronounced in other strains of mice.
Aluminium compounds are the most widely employed
adjuvants for human beings [27]. Their effectiveness is
associated with a deposit formation in the site of admin-
istration [28-30]. The mechanism responsible for the
adsorption of antigenic proteins to aluminium adjuvants
involves electrostatic forces and hydrophobic interac-
tions, among other physicochemical phenomena [20].
However, the use of aluminium compounds as adjuvants
is limited by their failure to stimulate cellular immune
responses, including those mediated by cytotoxic T cells
[19,20]. These compounds are known to induce a Th2
rather than Th1 immune responses [28-30], whereas
CFA, not licensed for use in human beings, usually
induces a mixed Th1-Th2 response [19,31]. These prop-
erties were confirmed in the present work.
The protective responses against some intracellular
pathogens, such as Leishmania and Mycobacterium,a r e
mediated by Th1 cells, both in mice [10,32] and in
human beings [1,4]. There is, therefore, a need for
highly efficacious, atoxic, Th1-promoting adjuvants, to
be used in vaccine preparations against these and other
pathogens. The Th1 cytokine profile induced by BAE
qualifies it as a promising candidate to become one of
these adjuvants. Indeed, the use of BAE as adjuvant led
to increased in vitro production of IFN-g and nitric
oxide by splenocytes, and both these biologically active
molecules have been shown to be positively involved in
the intracellular killing of Leishmania and Mycobacter-
ium [33,34]. In the case of Leishmania, however, the
present results suggest that particular parasite antigens
that do not induce Th2 immune responses, either by
their intrinsic nature or by amino-acid sequence manip-
ulation, should be used.
Advantages of the BAE, when compared with other
adjuvants, include the ample availability of the babassu
mesocarp, and its low cost of manufacture and ease of
formulation. The data presented herein justifies further
studies to identify the biologically active molecule(s) in
the BAE. Since Th1 cytokines may inhibit the develop-
ment of Th2 immune responses [32], the induction of
Th1 immune responses by BAE may therefore also be
useful in the control of diseases that are mediated by
Th2 immune responses, such as allergic asthma and
rhinitis.
Conclusions
Based on the present findings, it was possible to conclude
that: (i) BAE promotes preferentially a Th1-dependent
immune response in a Th2-prone strain of mice;
(ii) BAE, and/or biologically active molecules derived
from it, deserve to be further investigated as possible
adjuvants in candidate vaccines for leishmaniases and
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sibly in the immunotherapy of diseases that are mediated
by Th2 immune responses, such as allergic asthma and
rhinitis.
Methods
Mice
Male, 8-12 week-old Balb/c mice, weighing 20-25 g,
were from the Animal Breeding Unit of the Oswaldo
Cruz Foundation, Salvador, Brazil. The animals were
kept in ventilated cages, at 23 ± 1°C, with a relative
humidity of 44-56%, and light and dark cycles of 12 h.
They had free access to sterilized food and water. All
procedures involving the animals were reviewed and
approved by the institutional Ethics Committee in
Experimental Animal Use, in accordance with the Brazi-
lian College of Animal Experimentation.
Babassu and Leishmania extracts
Babassu mesocarp flour was purchased from ASSEMA
(São Luís, Maranhão, Brazil). This product was sub-
jected to analysis of authenticity, integrity and purity, by
physicochemical tests, including standard chromato-
graphic techniques. Similarities in all physicochemical
aspects were observed when it was compared with a
mesocarp flour prepared in our laboratory [17] from
babassu fruits collected from Pedreiras, State of Maran-
hão, Brazil (authenticated voucher specimen number
1135, filed in the Herbario Ático Seabra, São Luís, State
of Maranhão, Brazil).
Eighty grams of the mesocarp flour were extracted
during 1 h with 1 L of sterilized water, at 24°C, under
constant stirring. The aqueous extract was filtered in
0.22-μm Millipore™ units and then diluted in 0.15 M
phosphate-buffered saline, pH 7.2 (PBS), or culture
medium, to the appropriate concentrations for the in
vivo and in vitro studies. The composition of the extract,
as measured by high-pressure liquid chromatography
and gaseous chromatography, was: polysaccharides,
94.5%; proteins, 2.2%; lipids, 0.5%; monosaccharides and
disaccharides, 1.8%; amino acids, < 1.0%.
Promastigotes from the MHOM/Br87/Ba125 L. amazo-
nensis strain, derived from tissue amastigotes, were cul-
tured at 23°C in Schneider’s medium (Sigma-Aldrich Co.,
Saint Louis, MO, USA), pH 7.2, supplemented with 50
μg/mL of gentamycin and 10% of heat-inactivated fetal
bovine serum (FBS; HIFCS, Gibco Laboratories, Grand
Island, NY, USA). To prepare the LE, promastigotes were
washed three times in ice-cold sterile saline, resuspended
in ice-cold saline and lysed by exposition to ultrasound
(10 × 1-min cycles on ice). The lysates were centrifuged
at 16,000 g for 10 minutes at 4°C, the supernatants
filtered on membranes with 0.22 μm-diameter pores
(Millipore, São Paulo, Brazil) and immediately stored at
-70°C in small aliquots. Their protein content was deter-
mined by Lowry’s method [35].
Immunizations
Al(OH)3 gel (Alhydrogel; Sigma-Aldrich Co., Poole, UK),
at 1.3 mg/mL, was mixed with an equal volume of a solu-
tion containing LE (3.5 mg/mL) and BAE (80 mg/mL),
incubated at room temperature for 20 minutes and vor-
texed before utilization. Groups of 5 to 9 animals were
immunized by two subcutaneous injections of the Al
(OH)3 gel-adsorbed extracts, separated by a two-week
interval. Groups of 5-9 mice were also immunized, using
the same protocol, with LE emulsified in complete
Freund’sa d j u v a n t( C F A ;1m g / m Lo fMycobacterium
tuberculosis, Sigma-Aldrich Co., Poole, UK), with LE
mixed with BAE without Al(OH)3 gel, with Al(OH)3 gel-
adsorbed LE without BAE, and with BAE. The amounts
of LE and BAE in each injection were always 250 μga n d
5 mg, respectively. A negative control group was injected
with the diluent (saline) solution in place of the immu-
nizing injections.
Determination of antibody levels
Serum samples were prepared from blood collected ten
days after the last antigen or saline injection, for deter-
mination of anti-LE IgG1 and IgG2a antibody levels by
ELISA, as described previously [36]. Briefly, LE was
diluted to a concentration of 40 μg/mL in carbonate-
bicarbonate buffer (pH 9.6) and adsorbed onto wells of
flat-bottomed ELISA strips (NUNC, Roskilde, Denmark)
by overnight incubation at 4°C. The wells were then
washed five times with PBS containing 0.05% of Tween
20 (PBS-T) and incubated with PBS-T containing 1%
b o v i n es e r u ma l b u m i n( P B S - T A )f o r1ha t3 7 ° C .
Another wash as the described above was followed by
the addition of a 1/100 dilution of mouse sera in PBS-
TA. After 30 min at 37°C and further washing, 100 μL
of peroxidase-conjugatedg o a ta n t i - m o u s eI g G 1o r
IgG2a (PharMingen, San Diego, CA, USA), diluted
1:1000 in PBS-TA, were added to the wells and incu-
bated for 1 h at 37°C. The wells were then washed five
times with PBS-T and the colour was developed by add-
ing 100 μL of a solution of tetramethylbenzidine and
H2O2 and incubating in the dark for 20 min. The reac-
tion was stopped with 2 N H2SO4 and the optical den-
sity (OD) for 450 nm wave-length light was measured.
Cytokine quantification in spleen-cell cultures
Spleens were aseptically removed 10 days following the
booster. Cell suspensions were prepared by gently teasing
apart the splenic tissue in RPMI 1640 supplemented with
2 mM L-glutamine, 100 U/ml penicillin, 100 μg/mL strep-
tomycin, 0.05 mM 2-mercaptoethanol, and 10% FBS (Life
Technologies, Paisley, UK). Viable cells were enumerated
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Page 6 of 8in a Trypan blue exclusion assay. Cytokine production was
assessed by culturing splenocytes (10
6/mL) in 24-well flat-
bottom tissue culture plates (Costar, Cambridge, MA,
USA). All samples were incubated in duplicate (500 μL/
well) with LE (40 μg/well) or BAE (50 μg/well) or with
RPMI 1640 medium alone. Supernatants were harvested
after 24 and 48 h incubation at 37°C and 5% CO2,a n d
stored at -20°C until assayed. IFN-g, IL-4, and IL-10 were
quantified by commercial capture ELISA kits, according
to the manufacturer’s directions (eBiosciences, San
Diego, CA, USA). The detection limits of the ELISAs were
2p g / m Lf o rI F N - g and IL-4, and 4 pg/mL for IL-10.
Cytokine concentrations in the cell culture supernatants
were determined by interpolation of the obtained ODs
(for 492 nm-wave length light) values in cytokine standard
curves (which had r ≥ 0.99).
Nitric oxide concentration
Fifty-μL volumes of supernatants from unstimulated
splenocytes, incubated for 24 hours in vitro at 37°C, 5%
of CO2 atmosphere and cell density of 5.2 × 10
6/mL,
were collected and incubated with an equal volume of
Griess reagent (1% sulfanilamide, 0.1% naphthalene dia-
minedihydrochloride, 2.5% H3PO4)f o r1 0m i na tr o o m
temperature, to allow the accumulation of nitrite (a stable
end product of the NO reaction) [37]. The absorbance of
550 nm wave-length light was determined. Conversion of
absorbance to μM of NO was done by interpolation into
a standard curve obtained with known concentrations (5-
60 μM) of sodium nitrite in RPMI medium.
Statistical analysis
The statistical significances of differences among experi-
mental groups were determined, with the use of the
SPSS Statistics 17.0 program, by the Kruskal-Wallis and
Mann-Whitney U tests for whole experimental results
and pairwise comparisons, respectively. Values were
considered statistically significant when P ≤ 0.05.
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